[Effects of ticlopidine on the plasma levels of beta-thromboglobulin and thromboxane B2 in types 1 and 2 diabetics].
11 insulin-dependent and 19 non insulin-dependent diabetics with varying degrees of metabolic compensation and with high plasma levels of beta-thromboglobulin and thromboxane B2 were selected. Depending on the type of diabetes and the degree of glycaemia, control plasma levels of beta-thromboglobulin and thromboxane B2 were progressively lower after 14, 28 and 42 days of treatment with ticlopidine (500 mg/per day orally), than those encountered at the start of the study. It is concluded that ticlopidine influences plasma levels of beta-thromboglobulin and thromboxane B2 independently of the type and degree of metabolic compensation in diabetes mellitus.
D001609:Beta-Globulins / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D013876:Thiophenes / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood*; D013931:Thromboxanes / Q000097:blood*; D013988:Ticlopidine; D001620:beta-Thromboglobulin / Q000097:blood*
D001609:Beta-Globulins; D013876:Thiophenes; D013931:Thromboxanes; D001620:beta-Thromboglobulin; D013929:Thromboxane B2; D013988:Ticlopidine
Effetti della ticlopidina sui valori plasmatici della beta-tromboglobulina e del trombossano B2 rilevati in diabetici tipo 1 e 2.